Tazarotene - Ortho Dermatologics

Drug Profile

Tazarotene - Ortho Dermatologics

Alternative Names: IDP-123

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Valeant Pharmaceuticals International
  • Class Antiacnes; Antipsoriatics; Esters; Keratolytics; Nicotinic-acids; Pyrans; Pyridines; Retinoids
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Acne vulgaris

Most Recent Events

  • 27 Jul 2017 Valeant Pharmaceuticals International acquired Ortho Dermatologics in 2011 and changed the name of the later to Valeant Dermatology. Subsequently, in July 2017, it was rebranded to Ortho Dermatologics
  • 26 Jul 2017 Chemical structure information added
  • 01 Jul 2017 Valeant Pharmaceuticals initiates enrolment in a phase III trial for Acne vulgaris (In adolescents, In adults, In children, In the elderly) (Topical) (NCT03168334)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top